EMulate Therapeutics
Shaping A New Paradigm in Research and Therapeutics

For centuries, the effect of low-intensity magnetic fields on biological systems has driven exploration across a multitude of experimental clinical studies and research. In the 19th century, A.F. Von Middendorff (1815–1894), a pioneer in biomagnetic research who observed migratory birds, wrote, “The inner magnetic sense of our sailors of heaven takes on the function performed by a compass for ships.”

Fast-forward to the present day, magnetic fields are used extensively for various medical applications, including diagnostic imaging, increasing the rate of bone fracture and wound healing, pain management, and treatment of depression and obsessive-compulsive disorder. A significant battery of evidence from clinical research laboratories supports that exposure to extremely low-frequency magnetic fields produces biological responses, from cell culture to whole organisms. Although research on the biological effects of magnetic fields is just starting to delineate the critical parameters that can be exploited and used in medical applications, the scale of active, scientific testing aimed at understanding its mechanisms promises remarkable results.

In the pursuit of novel diagnostic and therapeutic medical applications, EMulate Therapeutics, Inc., a clinical-stage therapeutic device company, has developed a proprietary patented technology. It uses radio frequency spectrum (“ulRFE”), to specifically regulate signaling and metabolic pathways on the molecular and genetic levels without chemicals, radiation, or drugs.

“As the first true digital therapeutic company, our technology has consistently emulated the effects of drug and chemicals that have an underlying non-covalent mechanism of action,” explains Chris E. Rivera, CEO, President, and Chairman of EMulate Therapeutics. Its proprietary ulRFE® technology has been shown to be therapeutically beneficial with no significant adverse side effects for patients afflicted with glioblastoma and diffuse midline glioma, including diffuse intrinsic pontine glioma (DIPG), a rare but fatal brain tumor that usually afflicts young children. In addition, EMulate Therapeutics recently generated encouraging pre-clinical data in animal testing models and initial human testing for other indications. These data support safety and potential efficacy for patients suffering from chronic or acute pain and multiple mental health disorders.

EMulate Therapeutics’ proprietary ulRFE technology produces a broadband multi-frequency oscillating magnetic field, with frequencies from 0 kHz up to about 22 kHz., It is obtained from recordings of selected molecules derived using a proprietary Magnetic Interrogation Device System (MIDS).

The MIDS acts as an acquisition system, containing a target molecule solvated in a solution and supercooled to approximately four kelvin using liquid helium. Utilizing Nobel Prize-winning Superconducting Quantum Interference Device (SQUID) technology optimized by the U.S. military, the electrostatic surface potential of molecules is measured. During a typical recording session for pre-clinical studies, multiple dilutions are measured as a time-domain series, and the signals with the highest digital activity are identified and converted to WAV files.

While the details of the mechanism of action are in development, recordings are designed to capture non-covalent features of the recorded molecule that alter cellular behavior by emulating the chemical effects of drug therapy. Not only does EMulate’s technology essentially replicate many essential aspects of the therapeutic outcome of desired clinical treatments, with no observed toxicity or harmful side effects, but it also overcomes crucial obstacles to drug delivery. For example, in the case of brain cancer, the technology enables therapeutic treatment of the brain, which cannot be reached by the source molecule because of its inability to pass through the blood-brain barrier. As a result of over two decades of intensive research and experience, the company has been granted 41 U.S. and foreign patents (with another pending) for its proprietary technology platform.

In the current scenario, medical device manufacturing and pharmaceutical companies are re-examining steps to reduce hindrances such as pricing constraints, the cost of drug development, and complex manufacturing models.

The black swan events of the COVID-19 pandemic have brought new attention to common bottlenecks for clinical trial processes and underscored the need to optimize new drug discovery and development processes. “This is one of the orthogonal changes EMulate Therapeutics can make to the market. Our unique experience and patented technology enable us to develop a therapeutic effect from concept to conducting validated testing within a short period and at a significantly lower cost,” says Rivera.

EMulate Therapeutics was founded in 2002 with a focus on developing and commercializing novel therapies, using its disruptive platform to address a wide range of critical needs in healthcare conditions, veterinary medicine, and non-medical applications. The company’s patented ulRFE technology enables researchers to develop novel therapies, from concept molecule identification to validated pre-clinical safety and efficacy trials, within only six months to a year and cost-effectively ($250-500K).

“We are actively identifying partners and interesting collaborations with industry-leading companies that have expertise in specific vertical markets to help us accelerate the development of our technology and benefit more patients in the long-term,” adds Rivera.

EMulate Therapeutics, a disruptive company with multiple market potentials, focuses its business strategy on expanding the application of its patented ulRFE technology and building a comprehensive network of multiple independent subsidiary business units in various areas of human, animal, and plant health conditions. Currently, the company has incorporated one spinout company and four subsidiary companies under its umbrella - Hapbee Technologies, Indolor Therapeutics, Mensana Therapeutics, Cellsana Therapeutics, and most recently, Zoesana Animal Health. Hapbee Technologies was founded to deploy EMulate Therapeutics’ technology into the wellness wearable consumer space and is currently publicly traded on the TSXV Exchange. Hapbee has licensed EMulate’s proprietary technology for its target market(s), and in exchange EMulate receives a royalty on net sales, paid quarterly, and is Hapbee’s largest shareholder. Based on the strategic success of Hapbee, Emulate founded Indolor Therapeutics and Mensana Therapeutics’ to focus on therapies for patients suffering from a variety of severe pain conditions and mental health conditions respectively,. Likewise, Cellsana Therapeutics was incorporated earlier this year to boost oncology research and therapy development. As part of its latest partnership, Zoesana Animal Health will use EMulate Therapeutics’ proprietary radio frequency energy technology to develop and provide safe and effective therapies for companion animals suffering from various pathologies such as cancer, pain conditions, and anxiety.

Over the years, EMulate Therapeutics has made significant progress on multiple fronts. It is preparing to initiate pivotal Phase III human clinical trials in glioblastoma and diffuse midline glioma, including diffuse intrinsic pontine glioma. Its patented ulRFE technology has also shown safety and effectiveness in pre-clinical animal studies and is awaiting IRB approval for initial human trials in pain management and multiple mental health afflictions, including PTSD, anxiety, and more. EMulate Therapeutics has generated positive data in animal health and bio-agriculture models by treating 20 different kinds of solid tumors in over 300 pets and completing proof-of-concept studies in plant growth, photosynthesis, and weed control models.

For the future, EMulate Therapeutics aims to continually focus on enhancing its ulRFE technology, including increasing its user-friendliness, effectiveness, and predictability to advance pipeline capability, notably in the areas of medical, animal health, agriculture, and non-medical uses, which may be available through its licensees. As part of the project, the company is investigating new ways to improve the effects of its WAV files and modulate the effects based on the desired impact. The continued expansion of EMulate Therapeutics’ patent portfolio represents another significant step forward in its ongoing efforts to combat various diseases and provide alternatives in pharmaceutical and medical device markets with truly pioneering digital therapeutics.